Metabolism:血糖状态与胆道癌的关系

2021-08-09 MedSci原创 MedSci原创

IFG和糖尿病均与BTC风险增加独立相关,包括CCA和GBC。较长的糖尿病病程与BTC风险进一步增加相关。糖尿病甚至IFG可能是BTC可改变的危险因素。

糖尿病与胆道癌(BTC)风险之间的关联缺乏基于人群的证据。

近日,代谢性疾病领域权威杂志Metabolism-Clinical and Experimental上发表了一篇研究文章,该研究旨在评估韩国一般人群中糖尿病前期、糖尿病和糖尿病病程与随后发生BTC风险之间的关联,包括胆管癌(CCA)和胆囊癌(GBC)。

这项全国性队列研究纳入9697773名年龄20岁以上且未患癌症的成年人,他们在2009年1月至12月期间接受了全国健康筛查。受试者的血糖状态分为正常血糖、空腹血糖受损(IFG)、新诊断的糖尿病、糖尿病病程<5年和糖尿病病程≥5年。BTC是通过索赔数据来确定的。随访持续到2017年12月。Cox比例风险模型用于估计多变量调整的BTC风险比和95%CI。

胆道癌风险

在7.2年的中位随访期间,13022名患者被新诊断为BTC。与血糖正常组相比,IFG、新诊断糖尿病、糖尿病病程<5年和糖尿病病程≥5年组BTC调整后风险比(95%CI)分别为:1.08(1.04-1.12)、1.31(1.22-1.41)、1.35(1.27-1.43)和1.47(1.39-1.55)。BTC风险随着血糖状态的恶化而显著增加(趋势P<0.001)。这些结果与CCA和GBC分析的结果一致。

由此可见,IFG和糖尿病均与BTC风险增加独立相关,包括CCA和GBC。较长的糖尿病病程与BTC风险进一步增加相关。糖尿病甚至IFG可能是BTC可改变的危险因素。

原始出处:

Joo-Hyun Park.et al.Glycemic status and biliary tract cancer.Metabolism-Clinical and Experimental.2021.https://www.metabolismjournal.com/article/S0026-0495(21)00148-7/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896876, encodeId=452c18968e6a2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 17 16:48:22 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888325, encodeId=2e9718883250a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Mar 02 21:48:22 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577271, encodeId=3fae15e727191, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598129, encodeId=e074159812936, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630641, encodeId=56c21630641bd, content=<a href='/topic/show?id=0da289844bc' target=_blank style='color:#2F92EE;'>#血糖状态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89844, encryptionId=0da289844bc, topicName=血糖状态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeed21545240, createdName=naiwu84, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
    2022-07-17 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896876, encodeId=452c18968e6a2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 17 16:48:22 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888325, encodeId=2e9718883250a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Mar 02 21:48:22 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577271, encodeId=3fae15e727191, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598129, encodeId=e074159812936, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630641, encodeId=56c21630641bd, content=<a href='/topic/show?id=0da289844bc' target=_blank style='color:#2F92EE;'>#血糖状态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89844, encryptionId=0da289844bc, topicName=血糖状态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeed21545240, createdName=naiwu84, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
    2022-03-02 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896876, encodeId=452c18968e6a2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 17 16:48:22 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888325, encodeId=2e9718883250a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Mar 02 21:48:22 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577271, encodeId=3fae15e727191, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598129, encodeId=e074159812936, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630641, encodeId=56c21630641bd, content=<a href='/topic/show?id=0da289844bc' target=_blank style='color:#2F92EE;'>#血糖状态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89844, encryptionId=0da289844bc, topicName=血糖状态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeed21545240, createdName=naiwu84, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1896876, encodeId=452c18968e6a2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 17 16:48:22 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888325, encodeId=2e9718883250a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Mar 02 21:48:22 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577271, encodeId=3fae15e727191, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598129, encodeId=e074159812936, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630641, encodeId=56c21630641bd, content=<a href='/topic/show?id=0da289844bc' target=_blank style='color:#2F92EE;'>#血糖状态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89844, encryptionId=0da289844bc, topicName=血糖状态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeed21545240, createdName=naiwu84, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
    2021-08-11 仁心济世
  5. [GetPortalCommentsPageByObjectIdResponse(id=1896876, encodeId=452c18968e6a2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Jul 17 16:48:22 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888325, encodeId=2e9718883250a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Mar 02 21:48:22 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577271, encodeId=3fae15e727191, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598129, encodeId=e074159812936, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630641, encodeId=56c21630641bd, content=<a href='/topic/show?id=0da289844bc' target=_blank style='color:#2F92EE;'>#血糖状态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89844, encryptionId=0da289844bc, topicName=血糖状态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aeed21545240, createdName=naiwu84, createdTime=Wed Aug 11 03:48:22 CST 2021, time=2021-08-11, status=1, ipAttribution=)]

相关资讯

卡瑞利珠单抗联合GEMOX一线治疗胆道癌单臂探索性研究亮相ASCO舞台

胆道恶性肿瘤是一类恶性度较高、预后较差的肿瘤,一线化疗的疗效有限,二线治疗缺乏标准方案。江苏省人民医院研究团队的一项卡瑞利珠单抗联合GEMOX一线治疗胆管癌单臂探索性研究亮相2019年ASCO年会,其初步研究结果显示,这一联合方案的疗效和安全性均优,为胆道肿瘤开辟新的治疗策略提供了思路与研究基础。特邀主要研究者束永前教授和陈晓锋教授就该研究设计的初衷、主要研究结果和对未来的启示进行专访。

Eur J Cancer:非酒精性脂肪性肝病会增加胆道癌风险!

胆道癌(BTC),包括胆管癌和胆囊癌,是世界上第二常见的肝胆道癌症

默克(Merck KGaA)的胆道癌疗法Bintrafusp Alfa,研究结果令人失望

默克公司(Merck KGaA)周二宣布,Bintrafusp alfa二线治疗局部晚期或转移性胆道癌患者的试验未能达到其主要终点。

J Hepatol:FOSL1通过可能具有治疗靶向性的转录效应因子促进胆管癌的发生

研究揭示了FOSL1在胆管癌中的功能和临床相关性,以及可能通过药理学抑制实现新治疗策略的潜在靶点。

Lancet Oncol:积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期

近日,The Lancet Oncology发表研究显示对于一线化疗进展后的晚期胆道癌患者,在二线治疗采取积极症状控制联合FOLFOX方案(亚叶酸+氟尿嘧啶+奥沙利铂)可有效改善生存期。